Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Patent: 10,159,662

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,159,662
Title:Azetidine derivative, preparation method therefor, and use thereof
Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
Inventor(s): Xie; Yinong (Chengdu, CN), You; Zejin (Chengdu, CN), Deng; Zhiwen (Chengdu, CN), Zhu; Jun (Chengdu, CN), Wang; Ao (Chengdu, CN), Feng; Yan (Chengdu, CN), Long; Dong (Chengdu, CN), Zeng; Hong (Chengdu, CN), Song; Hongmei (Chengdu, CN), Ye; Qijun (Chengdu, CN), Qi; Wei (Chengdu, CN), Su; Donghai (Chengdu, CN), Wang; Lichun (Chengdu, CN), Wang; Jingyi (Chengdu, CN)
Application Number:15/767,508
Patent Claims:see list of patent claims

Details for Patent 10,159,662

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (Chengdu, CN) 2035-12-11 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (Chengdu, CN) 2035-12-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.